Novel Endolysin to Selectively Manage Antimicrobial Resistant S. aureus in Wound Biofilms

该博士生的目的是确定抗菌素耐药(AMR)金黄色葡萄球菌对皮肤老化和慢性伤口的贡献，同时测试针对金黄色葡萄球菌的新型内溶素技术治疗AMR金黄色葡萄球菌皮肤/伤口感染的选择性和有效性。博士项目将包括对患者样本的分析，以及在威尔金森/哈德曼教授和托马斯教授小组内进行的详细机械实验。该学生还将接受Cica Biomedical的行业安置，以帮助进行重要的临床前研究。这一博士项目涉及与Micreos Pharma合作研究新型内毒素的工作计划(过去两年，GB 400K直接资助)，以及国家生物膜创新中心之前的拨款(FTMA和POC奖，2021-2022年)，为这项研究产生了重要的试点数据。赫尔大学和赫尔·约克医学院也支持由比赛资助的学生，这将与NBIC的学生资格密切相关。

The purpose of this PhD studentship is to determine the contribution of antimicrobial resistant (AMR) S. aureus to skin ageing and chronic wounds, alongside testing the selectivity and efficacy of a novel S. aureus-targeted endolysin technology for the management of AMR S. aureus skin/wound infections. The PhD project will involve analysis of patient samples, alongside detailed mechanistic experiments carried out within the groups of Dr Wilkinson/Prof Hardman and Prof Thomas. The student will also undertake an industry placement with Cica Biomedical to assist with important pre-clinical studies. This PhD project relates to a program of work investigating novel endolysins with Micreos Pharma (£400K direct funding over last 2 years), and previous grants from the National Biofilms Innovation Centre (FTMA and POC awards 2021-2022) that have generated important pilot data for this studentship. A match-funded studentship has also been supported by the University of Hull and Hull York Medical School, which will closely align to the NBIC studentship.